Drug substance manufacturing
Structure manufacturer details, starting materials, process descriptions, in-process controls, and process validation information for section 3.2.S.2.
NARRATIVA · REGULATORY
CTD Module 3 (CMC) Authoring with AI Agents
Build the detailed quality record behind the summary. Organize drug substance and drug product manufacturing descriptions, specifications, stability.
AI AGENTS TRUSTED BY LIFE SCIENCES ORGANIZATIONS
CTD MODULE 3 · DETAILED QUALITY SOURCES
Document the detail.
Keep every source connected.
Module 3 contains the detailed quality information that supports the CTD. Work across the drug substance and drug product source sections, with traceable drafts and qualified CMC reviewers guiding each step.
Drug substance specifications
Bring specifications, analytical procedures, validation reports, and justifications together under the drug substance control section 3.2.S.4.
Drug substance stability
Organize stability protocols, study results, and proposed retest period or storage conclusions in section 3.2.S.7.
Drug product manufacturing
Describe composition, manufacturers, process steps, in-process controls, and process validation in section 3.2.P.3.
Drug product specifications & methods
Compile specifications, analytical procedures, validation reports, and justification of specifications for section 3.2.P.5.
Drug product stability
Bring stability protocols, reports, data, and shelf-life or storage conclusions together in section 3.2.P.8.
MEDICAL AUTHORING COMPANION · CMC QUALITY
Keep the evidence behind every quality conclusion.
CTD Module 3 is the detailed quality module of a Common Technical Document. It contains the drug substance and drug product information needed to describe how a medicine is manufactured, tested, controlled, and supported by stability data.
Medical Authoring Companion helps teams structure these source sections, prepare drafts from approved materials, and keep claims connected to their supporting descriptions, specifications, reports, and validation records. CMC experts remain responsible for technical interpretation, verification, and approval.
CTD MODULE 3 · CMC · FAQ
Detailed quality evidence, connected.
Learn how source-aware workflows can support CMC authoring and review across the detailed quality module.
What is CTD Module 3?
CTD Module 3 contains detailed quality information about the drug substance and drug product, including manufacture, control, specifications, analytical procedures, and stability, arranged according to the applicable CTD structure.
Which source sections are covered here?
The page highlights drug substance manufacture (3.2.S.2), control (3.2.S.4), and stability (3.2.S.7), plus drug product manufacture (3.2.P.3), control (3.2.P.5), and stability (3.2.P.8). The applicable dossier scope depends on the product and submission.
Where do analytical method validation records belong?
Analytical procedures and their validation information are presented within the relevant control sections, including drug substance section 3.2.S.4 and drug product section 3.2.P.5. The specific records and subsection structure follow the applicable CTD requirements.
How is Module 3 related to the Quality Overall Summary?
Module 3 holds the detailed supporting quality information. CTD Module 2.3 summarizes that information at a higher level. Source links and cross-document checks can help reviewers move between the concise summary and its underlying evidence.
How can AI agents support CMC authoring?
Configured agents can help organize approved source materials, draft structured sections, retain source references, and flag potential gaps or inconsistencies for review. CMC and regulatory experts verify the content and approve the submission.